Full TitleA Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently with an Anti-PD-L1 Antibody (Avelumab) in Patients with Advanced High-grade Sarcoma
This study is determining the safest dose of the investigational drug DCC-3014 that can be given with avelumab immunotherapy in patients with advanced or metastatic sarcomas. DCC-3014 may help fight cancer by targeting a type of white blood cell called a macrophage.
Macrophages are immune cells in or around tumors. Scientists have found that certain macrophages can block the immune system from fighting cancer. Some tumors do not respond to immunotherapy drugs alone because of these macrophages. DCC-3014 may stop macrophages from blocking the immune system and may allow immunotherapy to stimulate the immune system to fight cancer.
Avelumab works by blocking a protein in tumor cells called PD-L1. Tumor cells make PD-L1 to help them evade being detected by the immune system. By blocking this protein, avelumab may improve the ability of the immune system to find and destroy a cancer. Avelumab is given intravenously (by vein) and DCC-3014 is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have advanced or metastatic sarcoma that continues to grow despite at least one prior regimen of therapy.
- Patients should recover from the serious side effects of previous treatments before entering the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Sandra P. D’Angelo at 646-888-4159.